Global Blood Transfusion Diagnostics Market Overview

The global blood transfusion diagnostics market is projected to expand from US$ 4,096.93 million in 2021 to US$ 6,483.75 million by 2028, reflecting a compound annual growth rate (CAGR) of 6.9% from 2022 to 2028. This report outlines the key trends and factors propelling market growth.

Market Growth Drivers

The surge in the global blood transfusion diagnostics market can be primarily linked to the escalating prevalence of chronic diseases and the increasing demand for blood transfusions, particularly due to the rise in organ transplant surgeries. However, challenges associated with blood transfusion services pose significant barriers to market expansion.

Understanding Blood Transfusion Diagnostics

Blood transfusion diagnostics encompasses a series of tests conducted on blood and its components prior to their administration to patients. Blood transfusions are routine medical procedures where donated blood or its components are delivered to patients through an intravenous (IV) line. Each blood unit must undergo blood typing, which involves identifying the blood type and conducting screening tests to detect diseases, thereby preventing adverse reactions or the transmission of infections. Blood screening is performed using various instruments, kits, and reagents to identify diseases such as HIV, hepatitis B, hepatitis C, Zika virus, and other infections.

Prevalence of Chronic Diseases

According to data from the National Institute of Cancer Prevention and Research (NICPR) and the Indian Council of Medical Research (ICMR), the annual incidence of cancer in India is approximately 2.25 million, leading to a significant number of surgical interventions. A 2019 study titled "Challenges of Blood Transfusions in ?-thalassemia" indicated that around 26,000 patients with transfusion-dependent ?-thalassemia (TDT) are born each year, with about 90% of these cases occurring in low- or middle-income nations. Hemoglobinopathies, including sickle cell disease, are prevalent in regions such as Africa, Asia, the Middle East, the Indian subcontinent, and the Mediterranean. These conditions are now recognized as the most common rare inherited genetic disorders in Europe, with increasing cases in North America and Northern and Western Europe due to migration. In the UK, approximately 800 patients with thalassemia are registered, with around 500 receiving regular blood transfusions. Consequently, blood transfusion diagnostics are essential in various surgical procedures, including cardiac surgeries and other invasive operations.

Impact of Chronic Diseases on Blood Transfusion

Chronic illnesses such as cancer, cardiovascular diseases, and renal disorders are leading causes of mortality globally. These conditions often necessitate surgical procedures that carry the risk of significant blood loss, requiring fresh blood transfusions to maintain adequate blood levels. Blood transfusion diagnostics play a crucial role during these transfusion processes, contributing to the market's growth in response to the rising incidence of chronic diseases.

Market Segmentation

The global blood transfusion diagnostics market is categorized based on product type, application, and end user. The product segment is divided into instruments & kits and reagents. In 2021, the instruments & kits segment dominated the market and is anticipated to exhibit a higher CAGR from 2022 to 2028. In terms of application, the market is split into disease screening and blood grouping, with the disease screening segment holding a larger market share in 2021 and expected to grow at a faster rate during the forecast period. The end-user segment includes blood banks, hospitals, diagnostic laboratories, and plasma fractionation companies, with blood banks leading the market share in 2021 and projected to maintain the highest growth rate through 2028.

COVID-19 Pandemic Effects

The COVID-19 pandemic had a detrimental effect on blood service operations globally. Blood collection efforts were hampered due to reduced donor availability, stemming from public health measures such as social distancing and the cancellation of blood donation drives. This decline in blood collection resulted in a shortage of blood for transfusions. A study by RMIT University found that blood donations in Australia decreased by an average of 38%. In response to the blood shortage, various campaigns were launched to encourage blood donation and raise awareness about its importance. For example, the Korean Red Cross Blood Services (KRCBS) successfully requested the Ministry of Health and Welfare to relax geographical restrictions related to indigenous malaria, allowing for the collection of over 23,000 units of whole blood. Additionally, medical professionals took steps to minimize unnecessary blood transfusions, as highlighted by reports from ABC Science in March 2022, which noted warnings against unnecessary transfusions in Australian hospitals. The restrictions on medical and surgical practices also contributed to a reduced need for blood transfusions, indicating a negative impact on the blood transfusion diagnostics market due to the pandemic.

Market Strategies and Developments

Companies in the global blood transfusion diagnostics market are employing various organic and inorganic strategies to enhance their market presence. Organic strategies primarily involve product launches and approvals, while inorganic strategies include acquisitions, collaborations, and partnerships. These strategies enable market players to expand their operations and improve their geographic reach, thereby fostering overall market growth. Significant developments in the market include:

• July 2022: Quotient Limited entered into an agreement with InfYnity Biomarkers to enhance the safety and effectiveness of infectious disease testing using Quotient's MosaiQ solution.


• November 2021: Roche launched the cobas 5800 System, a new molecular laboratory instrument designed to address laboratory challenges while providing timely and meaningful results.

In preparing this report on the global blood transfusion diagnostics market, key sources included the National Health and Medical Research Council (NHMRC), the Government of Canada, and the Kidney Research and Clinical Practice (KRCP).